Jinyu Bio-Technology

Jinyu Bio-Technology

Jinyu Bio-Technology was established in 1993 by Chongyu Zhang in Hohhot, Inner Mongolia, and became one of China's first publicly traded animal-health companies when it listed on the Shanghai Stock Exchange in 1998. Zhang remains Chairman and legal representative, while his daughter Jing Zhang serves as President and Vice Chairman, embedding family succession into the corporate governance structure. The wealth origin is transparent and operational: the firm manufactures and sells veterinary biopharmaceuticals at scale across China's livestock sector. Strategy flows directly from the manufacturing base. The firm invests via its corporate balance sheet — not third-party LP capital — targeting biotechnology ventures that complement its vaccine production lines. Asset classes include direct private equity, joint-venture R&D partnerships, and real assets tied to laboratory and production infrastructure. The joint development with Beijing HeSheng Gene Technology on mRNA vaccine projects signals an acceleration into next-generation platforms beyond traditional inactivated vaccines. Geographic footprint spans domestic manufacturing in Hohhot, commercial offices in Beijing and Shanghai, and a research facility in Manhattan, Kansas — indicating a dual-country R&D strategy that accesses US veterinary science talent. Deployment scale is not publicly disclosed because the firm operates as a listed corporate investor rather than a committed fund vehicle. The known operational footprint includes the Jinyu International Biotechnology Industrial Park in Hohhot, the Beijing and Shanghai office buildings, and the Kansas research facility — a physical-plant network that supports both manufacturing and early-stage R&D. The firm maintains membership in the China General Chamber of Commerce — USA, consistent with its cross-border presence. Adjacent structures include the Jinyu Family Fund, a philanthropic vehicle that formalizes the founding family's charitable activities. Structurally, Jinyu differs from a conventional family office because the investment function sits inside a publicly traded operating company. Deployment decisions are balance-sheet allocations by a listed entity, subject to minority-shareholder disclosures and SSE regulatory oversight, rather than private-family mandates. That structure creates a transparent — if slower — investment process, where scientific adjacency to the core animal-health business drives deal selection rather than pure financial return.